CFRXQ Stock - ContraFect Corporation
Unlock GoAI Insights for CFRXQ
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-154,000 | $-148,000 | $-168,249 | $-169,159 | $-151,292 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-56,889,000 | $-47,265,000 | $-34,239,590 | $-27,866,450 | $-32,346,420 |
| Net Income | $-65,153,000 | $-20,282,000 | $-28,155,673 | $-12,794,493 | $-37,684,424 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-124.97 | $-44.12 | $-98.95 | $-123.57 | $-396.35 |
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus. The company also developing CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also developing CF-296, an osteomyelitis and PJI which is in preclinical trailers for the treatment of joint infections. In addition, the company developing Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. Further, It develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York. On December 4, 2023, ContraFect Corporation filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.
Visit WebsiteEarnings History & Surprises
CFRXQEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2025 | May 2, 2025 | — | — | — | — |
Q1 2025 | Mar 27, 2025 | — | — | — | — |
Q4 2024 | Dec 26, 2024 | — | — | — | — |
Q3 2024 | Jul 23, 2024 | $-0.69 | — | — | — |
Q2 2024 | Jun 13, 2024 | — | — | — | — |
Q1 2024 | Mar 29, 2024 | $-0.69 | — | — | — |
Q4 2023 | Nov 14, 2023 | $-0.66 | $-0.50 | +24.1% | ✓ BEAT |
Q3 2023 | Aug 14, 2023 | $-1.81 | $-1.94 | -7.2% | ✗ MISS |
Q1 2023 | Mar 31, 2023 | $-10.83 | $-0.69 | +93.6% | ✓ BEAT |
Q4 2022 | Dec 31, 2022 | $-27.20 | $-16.14 | +40.7% | ✓ BEAT |
Q3 2022 | Sep 29, 2022 | $-18.40 | $-34.71 | -88.7% | ✗ MISS |
Q2 2022 | Jun 29, 2022 | $-26.40 | $-36.79 | -39.4% | ✗ MISS |
Q1 2022 | Mar 30, 2022 | — | $-41.00 | — | — |
Q4 2021 | Dec 30, 2021 | $-25.80 | $-8.83 | +65.8% | ✓ BEAT |
Q3 2021 | Sep 29, 2021 | — | $-10.76 | — | — |
Latest News
Frequently Asked Questions about CFRXQ
What is CFRXQ's current stock price?
What is the analyst price target for CFRXQ?
What sector is ContraFect Corporation in?
What is CFRXQ's market cap?
Does CFRXQ pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to CFRXQ for comparison